Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of bone
0.040 Biomarker disease BEFREE To determine quality of life (QoL) outcomes after palliation of pain from bone metastases using magnetic resonance-guided high intensity focused ultrasound (MR-guided HIFU), measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL and the QLQ-BM22 questionnaires. 29317145 2018
Secondary malignant neoplasm of bone
0.040 Biomarker disease BEFREE Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) bone metastases module (QLQ-BM22) and EORTC QOL Core-15-Palliative (QLQ-C15-PAL) before treatment and at days 10 and 42 after a single 8 Gy radiation treatment. 29156903 2017
Secondary malignant neoplasm of bone
0.040 Biomarker disease BEFREE Fifty-two patients who received a single 8-Gy RT for painful bone metastases completed the EORTC QOL-C15-PAL questionnaire prior to randomization and at 42-day post RT. 29156910 2017
Secondary malignant neoplasm of bone
0.040 Biomarker disease BEFREE Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points. 28196208 2017